Q-omics provides the consensus-scored RPS17P8 profile across patient tissues and cancer cell-line models. RPS17P8 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RPS17P8 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, RPS17P8 RNA expression shows 4,233 significant pathway-activity associations, with the highest sampling consensus in PRAD. Together, these results highlight KIRC, and PRAD as cancer lineages where RPS17P8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS17P8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS17P8 survival associations across molecular data types. RPS17P8 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS17P8 RNA expression–survival associations across cancer types. High RPS17P8 expression shows unfavorable associations in MESO, KIRP and TGCT, but favorable associations in KIRC, UCS and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .007). Together, the overview and detailed table identify KIRC as the clearest survival context for RPS17P8 RNA expression.
This table summarizes RPS17P8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS17P8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS17P8 shows higher tumor expression in KIRC, THCA, PRAD and LIHC. The KIRC box plot shows higher RPS17P8 RNA expression in tumor versus normal tissue (log2 FC = +0.215, t-test p < 0.001).
This table shows molecular features associated with RPS17P8 in patient tissues and cancer cell lines. In patient samples, RPS17P8 shows the broadest associations at the RNA and protein expression levels, with PRAD recurring as the lineage with the largest associated feature set.
